We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to ...

The challenger sports drink brand tells The Drum that it is doubling down on what’s working as it refreshes everything from ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Recent consumer research by product development group AMC Global and OpinionRoute, LLC reveals the evolving preferences of ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Leerink notes Eli Lilly’s (LLY) once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average<a class="excerpt-read-more" href=" More ...

A new oral GLP-1 drug candidate could transform the diabetes and weight loss drug boom. Why it matters: Eli Lilly said on ...

Days after Pfizer Inc. pulled the plug on its oral GLP-1 candidate danuglipron, Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.